# Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer

> **NCT03658772** · PHASE1 · COMPLETED · sponsor: **Arrys Therapeutics** · enrollment: 54 (actual)

## Conditions studied

- Microsatellite Stable Colorectal Cancer

## Interventions

- **DRUG:** grapiprant
- **DRUG:** grapiprant and pembrolizumab

## Key facts

- **NCT ID:** NCT03658772
- **Lead sponsor:** Arrys Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-20
- **Primary completion:** 2023-03-07
- **Final completion:** 2023-03-07
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2023-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03658772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03658772, "Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03658772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*